Graham P. Allaway - Concepedia

Author

Graham P. Allaway

Progenics Pharmaceuticals (United States)

Also Known As

Allaway, Graham P., G Allaway, G P Allaway, G. P. Allaway, GRAHAM P. ALLAWAY, Graham Allaway, Graham P Allaway, Graham P. Allaway, Nitz, Theodore, Qian, Keduo

Publications

Citations

H-Index

Concepts

All Affiliations

Progenics Pharmaceuticals (United States)Aaron Diamond AIDS Research Center National Institutes of Health University of North Carolina at Chapel Hill Rockefeller University

About

Graham P. Allaway is an author at Progenics Pharmaceuticals (United States) specializing in medicine, immunology, and virology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	24	6.4K
2	Natural Sciences	7	7	1K
3	Allergy	3	3	90
4	Biochemistry	2	2	79
5	Biology	1	1	20

Graham P. Allaway

Publications

7.7K

Citations

H-Index

Page 1

	Year	Citations
HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5 Tatjana Dragic, Virginia Litwin, Graham P. Allaway, Nature Cd4+ CellsHuman RetrovirusImmunologyAntiviral ResponseImmunologic Mechanism	1996	3.2K
CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5 Alexandra Trkola, Tatjana Dragic, James Arthos, Nature Human RetrovirusImmunologyAntiviral ResponseChronic Viral InfectionHiv	1996	1K
AMD3100, a small molecule inhibitor of HIV-1 entry via the CXCR4 co-receptor G A Donzella, Dominique Schols, Steven Lin, Nature Medicine MedicineNatural SciencesCxcr4 Co-receptorImmunologyHuman Retrovirus	1998	759
Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG Alexandra Trkola, A B Pomales, Huanhuan Yuan, Journal of Virology ImmunologyMolecular BiologyViral Structural ProteinImmunotherapyPrimary Hiv-1 Isolates	1995	477
PA-457: A potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing Feng Li, Ritu Goila-Gaur, Karl Salzwedel, Proceedings of the National Academy of Sciences	2003	426
Expression and Characterization of CD4-IgG <sub>2</sub> , a Novel Heterotetramer That Neutralizes Primary HIV Type 1 Isolates Graham P. Allaway, Karen Davis‐Bruno, Gary A. Beaudry, AIDS Research and Human Retroviruses	1995	231
Amino-Terminal Substitutions in the CCR5 Coreceptor Impair gp120 Binding and Human Immunodeficiency Virus Type 1 Entry Tatjana Dragic, Alexandra Trkola, Steven Lin, Journal of Virology	1998	216
Phase I and II Study of the Safety, Virologic Effect, and Pharmacokinetics/Pharmacodynamics of Single-Dose 3-<i>O</i>-(3′,3′-Dimethylsuccinyl)Betulinic Acid (Bevirimat) against Human Immunodeficiency Virus Infection Patrick F. Smith, Abayomi Ogundele, Alan Forrest, Antimicrobial Agents and Chemotherapy	2007	192
Cell surface expression of the 70-kD component of Ku, a DNA-binding nuclear autoantigen. Bellur S. Prabhakar, Graham P. Allaway, J. Srinivasappa, Journal of Clinical Investigation Proteinlipid InteractionImmunologyMolecular BiologyAntigen ProcessingCytoskeleton	1990	101
Susceptibility of Human Immunodeficiency Virus Type 1 to the Maturation Inhibitor Bevirimat Is Modulated by Baseline Polymorphisms in Gag Spacer Peptide 1 Kurt Van Baelen, Karl Salzwedel, Evelien Rondelez, Antimicrobial Agents and Chemotherapy Primary ImmunodeficiencyGag SpacerBaseline SusceptibilityHuman RetrovirusPathogenesis	2009	88

Page 1